Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities

被引：1
作者：
Chen, Minglong [1 ]
Zhou, Yue [2 ]
Fu, Yanping [2 ]
Wang, Qingqing [3 ]
Wu, Chuanbin [2 ]
Pan, Xin [4 ]
Quan, Guilan [2 ]
机构：
[1] Univ Sci & Technol China, Dept Polymer Sci & Engn, Hefei 230026, Anhui, Peoples R China
[2] Jinan Univ, Coll Pharm, Guangzhou 510632, Peoples R China
[3] Bengbu Med Coll, Pharm, Bengbu, Peoples R China
[4] Sun Yat sen Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China
来源：
EXPERT OPINION ON DRUG DELIVERY | 2024年 / 21卷 / 07期
基金：
中国国家自然科学基金;
关键词：
Cancer vaccines; biomaterialbased delivery; immune response; immunotherapy; IMMUNE CHECKPOINT BLOCKADE; DENDRITIC CELLS; IN-VIVO; MICRONEEDLE ARRAYS; RNA DELIVERY; ANTIGEN; THERAPY; NANOPARTICLE; INFLAMMATION; SCAFFOLDS;
D O I：
10.1080/17425247.2024.2388832
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
IntroductionCancer vaccines (protein and peptide, DNA, mRNA, and tumor cell) have achieved remarkable success in the treatment of cancer. In particular, advances in the design and manufacture of biomaterials have made it possible to control the presentation and delivery of vaccine components to immune cells.Areas coveredThis review summarizes findings from major databases, including PubMed, Scopus, and Web of Science, focusing on articles published between 2005 and 2024 that discuss biomaterials in cancer vaccine delivery.Expert opinionThe development of cancer vaccines is hindered by several bottlenecks, including low immunogenicity, instability of vaccine components, and challenges in evaluating their clinical efficacy. To transform preclinical successes into viable treatments, it is essential to pursue continued innovation, collaborative research, and address issues related to scalability, regulatory pathways, and clinical validation, ultimately improving outcomes against cancer.
引用
收藏
页码：1143 / 1154
页数：12
相关论文
共 92 条
  • [1] Targeting immunogenic cell death in cancer
    Ahmed, Asma
    Tait, Stephen W. G.
    [J]. MOLECULAR ONCOLOGY, 2020, 14 (12) : 2994 - 3006
  • [2] Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
    Alameh, Mohamad-Gabriel
    Tombacz, Istvan
    Bettini, Emily
    Lederer, Katlyn
    Sittplangkoon, Chutamath
    Wilmore, Joel R.
    Gaudette, Brian T.
    Soliman, Ousamah Y.
    Pine, Matthew
    Hicks, Philip
    Manzoni, Tomaz B.
    Knox, James J.
    Johnson, John L.
    Laczko, Dorottya
    Muramatsu, Hiromi
    Davis, Benjamin
    Meng, Wenzhao
    Rosenfeld, Aaron M.
    Strohmeier, Shirin
    Lin, Paulo J. C.
    Mui, Barbara L.
    Tam, Ying K.
    Kariko, Katalin
    Jacquet, Alain
    Krammer, Florian
    Bates, Paul
    Cancro, Michael P.
    Weissman, Drew
    Prak, Eline T. Luning
    Allman, David
    Locci, Michela
    Pardi, Norbert
    [J]. IMMUNITY, 2021, 54 (12) : 2877 - +
  • [3] Molecular insight of regorafenib treatment for colorectal cancer
    Arai, Hiroyuki
    Battaglin, Francesca
    Wang, Jingyuan
    Lo, Jae Ho
    Soni, Shivani
    Zhang, Wu
    Lenz, Heinz-Josef
    [J]. CANCER TREATMENT REVIEWS, 2019, 81
  • [4] Injectable cryogel-based whole-cell cancer vaccines
    Bencherif, Sidi A.
    Sands, R. Warren
    Ali, Omar A.
    Li, Weiwei A.
    Lewin, Sarah A.
    Braschler, Thomas M.
    Shih, Ting-Yu
    Verbeke, Catia S.
    Bhatta, Deen
    Dranoff, Glenn
    Mooney, David J.
    [J]. NATURE COMMUNICATIONS, 2015, 6
  • [5] Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
    Brudno, Jennifer N.
    Kochenderfer, James N.
    [J]. BLOOD REVIEWS, 2019, 34 : 45 - 55
  • [6] Translating Tumor Antigens into Cancer Vaccines
    Buonaguro, Luigi
    Petrizzo, Annacarmen
    Tornesello, Maria Lina
    Buonaguro, Franco M.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2011, 18 (01) : 23 - 34
  • [7] Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer
    Callmann, Cassandra E.
    Cole, Lisa E.
    Kusmierz, Caroline D.
    Huang, Ziyin
    Horiuchi, Dai
    Mirkin, Chad A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (30) : 17543 - 17550
  • [8] Extra-Large Pore Mesoporous Silica Nanoparticles Enabling Co-Delivery of High Amounts of Protein Antigen and Toll-like Receptor 9 Agonist for Enhanced Cancer Vaccine Efficacy
    Cha, Bong Geun
    Jeong, Ji Hoon
    Kim, Jaeyun
    [J]. ACS CENTRAL SCIENCE, 2018, 4 (04) : 484 - 492
  • [9] Chaudhary N, 2021, NAT REV DRUG DISCOV, V20, P817, DOI 10.1038/s41573-021-00283-5
  • [10] Oncology Meets Immunology: The Cancer-Immunity Cycle
    Chen, Daniel S.
    Mellman, Ira
    [J]. IMMUNITY, 2013, 39 (01) : 1 - 10
12345678910